The reissued notice of funding opportunity (NOFO) SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late-Stage Development (SB1, Clinical Trial Not Allowed) (PAR-23-219) encourages applications from small business concerns (SBCs) to the newly re-authorized CRP program.
Note: Though NIH also supports SBIR/STTR Commercialization Readiness Pilot (CRP) Program Technical Assistance and Late-Stage Development (SB1, Clinical Trial Required) (PAR-23-220), NIAID participates in only PAR-23-219.
The NOFO aims to facilitate the transition of previously or currently funded Small Business Innovation Research (SBIR) and Small Business Technology Transfer (STTR) Phase II and Phase IIB projects to the commercialization stage by providing additional support for technical assistance and later stage research and development (R&D) not typically supported through Phase II or Phase IIB grants or contracts, which may include the following:
- Independent replication of key studies
- Investigational new drug (IND)-enabling studies
- Clinical studies, manufacturing costs, regulatory assistance, or a combination of services
Examples of topic areas appropriate for this NOFO are listed under the Scientific/Technical Scope section of the NOFO.
Although a significant amount of the work in a CRP award may be subcontracted to other institutions, the SBC is expected to maintain oversight and management of the R&D throughout the award.
Keep in mind the following:
- All applicants should submit a new application (Type 1) regardless of whether the Phase II award is active or has ended.
- The standard resubmission policy applies as long as applicants have a qualifying Phase II application.
Small businesses with an active NIH SBIR or STTR Phase II or Phase IIB contract or grant award from one of the participating NIH institutes or centers within the last 36 months are eligible to submit applications for this opportunity. Only one CRP award is allowed per project.
NIAID will consider awards up to $1,000,000 per year for up to 3 years.
See the Key Dates section of the NOFO for application due dates. All applications are due by 5 p.m. local time of the applicant organization.
We encourage applicants to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date, the first of which is September 5, 2023.
Have Questions?
If so, direct them to NIAID’s scientific research contact Dr. Natalia Kruchinin at natalia.kruchinin@nih.gov or 240-669-2919. Also check NIH’s answers to frequently asked questions on Phase IIB and Commercialization Readiness Pilot (CRP) Program.